Interferons in Systemic Lupus Erythematosus

Rheum Dis Clin North Am. 2021 Aug;47(3):297-315. doi: 10.1016/j.rdc.2021.04.001. Epub 2021 Jun 10.ABSTRACTSkewing of type I interferon (IFN) production and responses is a hallmark of systemic lupus erythematosus (SLE). Genetic and environmental contributions to IFN production lead to aberrant innate and adaptive immune activation even before clinical development of disease. Basic and translational research in this arena continues to identify contributions of IFNs to disease pathogenesis, and several promising therapeutic options for targeting of type I IFNs and their signaling pathways are in development for treatment of SLE patients.PMID:34215365 | PMC:PMC8254852 | DOI:10.1016/j.rdc.2021.04.001
Source: The Medical Clinics of North America - Category: General Medicine Authors: Source Type: research